Cargando…

Development of De Novo Donor Specific Antibodies Following COVID-19 Vaccination in Cardiac Transplant

PURPOSE: Some transplant patients mount an insufficient response to standard COVID-19 vaccine (COVAX) dosing and a booster dose has now been approved. Vaccination carries the theoretical risk of stimulating antibody production to the donor. There are no prior studies surveying de novo donor specific...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maybaum, S., Rahman, A., Malhame, K., Rossi, D., Wallach, F., Kon, Z., Stevens, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2022
Materias:	(782)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988555/ http://dx.doi.org/10.1016/j.healun.2022.01.803

Ejemplares similares

(756) Immunogenicity of COVID-19 Vaccination in Cardiac Transplant Recipients: 5 Months Follow-Up after the 3rd Dose
por: Rahman, A., et al.
Publicado: (2023)

Letter to the Editor: Immunogenicity After the Third Dose of COVID-19 Vaccine in Cardiac Transplantation
por: Rahman, Afsana, et al.
Publicado: (2023)

Incidence and Clinical Significance of De Novo Donor Specific Antibodies after Kidney Transplantation
por: Lionaki, Sophia, et al.
Publicado: (2013)

The natural history of de novo donor-specific HLA antibodies after kidney transplantation
por: López del Moral, Covadonga, et al.
Publicado: (2022)

Clinical significance of de novo donor-specific antibody in kidney transplant recipients with chronic antibody-mediated rejection
por: Park, Woo Yeong, et al.
Publicado: (2021)

Characteristics and Clinical Significance of De Novo Donor-Specific Anti-HLA Antibodies after Kidney Transplantation
por: Jung, Hee-Yeon, et al.
Publicado: (2018)

Association between longer hospitalization and development of de novo donor specific antibodies in simultaneous liver–kidney transplant recipients
por: Yazawa, Masahiko, et al.
Publicado: (2019)

Role of de novo DQ donor-specific antibody in antibody-mediated rejection in renal transplant recipient: A case study
por: Chowdhry, Mohit, et al.
Publicado: (2019)

Importance and What to Watch Out for De Novo Donor Specific Anti-HLA Antibodies after Kidney Transplantation
por: Yang, Chul Woo
Publicado: (2018)

Utility of Protocol Pancreas Biopsies for De Novo Donor-specific Antibodies
por: Parajuli, Sandesh, et al.
Publicado: (2022)

Immunology and Donor-Specific Antibodies in Corneal Transplantation
por: Major, Joanna, et al.
Publicado: (2021)

The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients
por: O'Leary, Jacqueline G., et al.
Publicado: (2016)

Age-associated decrease in de novo donor-specific antibodies in renal transplant recipients reflects changing humoral immunity
por: von Moos, Seraina, et al.
Publicado: (2019)

Influence of a low-dose tacrolimus protocol on the appearance of de novo donor-specific antibodies during 7 years of follow-up after renal transplantation
por: Unagami, Kohei, et al.
Publicado: (2020)

Effect of donor-specific antibodies and panel reactive antibodies in living donor liver transplant recipients
por: Song, Seung Hwan, et al.
Publicado: (2015)

Vitamin D Receptor Activity, Vitamin D Status, and Development of De-novo Donor-specific Antibody after Renal Transplantation
por: Mehrotra, Sonia, et al.
Publicado: (2020)

De Novo Donor Specific Antibody and Long-Term Outcome After Liver Transplantation: A Systematic Review and Meta-Analysis
por: Beyzaei, Zahra, et al.
Publicado: (2020)

Biopsy findings after detection of de novo donor-specific antibodies in renal transplant recipients: a single center experience
por: Waldecker, Christoph B., et al.
Publicado: (2021)

Occurrence of De novo Donor-Specific Antibodies After COVID-19 in Kidney Transplant Recipients Is Low Despite Immunosuppression Modulation
por: Masset, Christophe, et al.
Publicado: (2022)

(60) Impact of Donor Specific Antibodies in Cardiac Transplant Recipients after Acute Covid-19
por: Martissa, J.A., et al.
Publicado: (2023)

Association between SARS-CoV-2 infection and de novo HLA donor specific antibody production in lung transplant recipients: Single-center study
por: Shah, Sadia Z., et al.
Publicado: (2022)

De Novo Donor‐Specific HLA Antibody Formation in Two Patients With Crigler‐Najjar Syndrome Type I Following Human Hepatocyte Transplantation With Partial Hepatectomy Preconditioning
por: Jorns, C., et al.
Publicado: (2015)

High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation
por: Del Bello, Arnaud, et al.
Publicado: (2018)

CXCR5(+)PD1(+)ICOS(+) Circulating T Follicular Helpers Are Associated With de novo Donor-Specific Antibodies After Renal Transplantation
por: Danger, Richard, et al.
Publicado: (2019)

Circulating de novo Donor Specific Antibodies and Carotid Intima-media Thickness in Pediatric Kidney Transplant Recipients, A Pilot Study
por: Sgambat, Kristen, et al.
Publicado: (2020)

Development of De Novo Donor-specific HLA Antibodies and AMR in Renal Transplant Patients Depends on CYP3A5 Genotype
por: Friebus-Kardash, Justa, et al.
Publicado: (2021)

Dynamic Behaviour of Donor Specific Antibodies in the Early Period Following HLA Incompatible Kidney Transplantation
por: Phillpott, Mason, et al.
Publicado: (2022)

Belatacept Treatment of Recurrent Late-onset T Cell–mediated Rejection/Antibody-mediated Rejection With De Novo Donor-specific Antibodies in a Liver Transplant Patient
por: Klintmalm, Göran B., et al.
Publicado: (2022)

Differential effects of donor‐specific HLA antibodies in living versus deceased donor transplant
por: Kamburova, E. G., et al.
Publicado: (2018)

Donor specific HLA antibody in hematopoietic stem cell transplantation: Implications for donor selection
por: Krummey, Scott M., et al.
Publicado: (2022)

Behaviour of Non-Donor Specific Antibodies during Rapid Re-Synthesis of Donor Specific HLA Antibodies after Antibody Incompatible Renal Transplantation
por: Krishnan, Nithya S., et al.
Publicado: (2013)

Characteristics of Donor-Specific Antibodies Associated With Antibody-Mediated Rejection in Lung Transplantation
por: Roux, Antoine, et al.
Publicado: (2017)

Donor HLA−DR Drives the Development of De Novo Autoimmunity Following Lung and Heart Transplantation
por: Jankowska−Gan, Ewa, et al.
Publicado: (2020)

An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies
por: Prémaud, Aurélie, et al.
Publicado: (2017)

Comparison of high-dose IVIG and rituximab versus rituximab as a preemptive therapy for de novo donor-specific antibodies in kidney transplant patients
por: Kim, Hyung Woo, et al.
Publicado: (2023)

Clinical Outcome of Kidney Transplant Recipients with C1q-Binding De Novo Donor Specific Antibodies: A Single-Center Experience
por: Marinaki, Smaragdi, et al.
Publicado: (2023)

Living Donor Kidney Transplantation in Patients With Donor-Specific HLA Antibodies After Desensitization With Immunoadsorption
por: Kälble, Florian, et al.
Publicado: (2021)

The impact of preformed donor‐specific antibodies in living donor liver transplantation according to graft volume
por: Goto, Ryoichi, et al.
Publicado: (2022)

Desensitization using IVIG alone for living-donor kidney transplant: impact on donor-specific antibodies
por: Ulisses, Luiz Roberto de Sousa, et al.
Publicado: (2022)

Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients
por: Lee, Hyeyoung, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_oq63pa6vc3dr72qtb7at51dnt3